Literature DB >> 31171642

Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells.

Inge Baas1, Laura Delvasto-Nuñez1,2, Peter Ligthart3, Conny Brouwer3, Claudia Folman3, Edimara S Reis4, Daniel Ricklin4,5, John D Lambris4, Diana Wouters1, Masja de Haas3,6,7, Ilse Jongerius1, Sacha S Zeerleder8,7,9,10.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31171642      PMCID： PMC7012486          DOI： 10.3324/haematol.2019.216028

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease.

Authors:  Alexander Röth; Andreas Hüttmann; Russell P Rother; Ulrich Dührsen; Thomas Philipp
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

2.  Safety profile after prolonged C3 inhibition.

Authors:  Edimara S Reis; Nadja Berger; Xin Wang; Sophia Koutsogiannaki; Robert K Doot; Justin T Gumas; Periklis G Foukas; Ranillo R G Resuello; Joel V Tuplano; David Kukis; Alice F Tarantal; Anthony J Young; Tetsuhiro Kajikawa; Athena M Soulika; Dimitrios C Mastellos; Despina Yancopoulou; Ali-Reza Biglarnia; Markus Huber-Lang; George Hajishengallis; Bo Nilsson; John D Lambris
Journal:  Clin Immunol       Date:  2018-10-10       Impact factor: 3.969

3.  C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia.

Authors:  Diana Wouters; Femke Stephan; Paul Strengers; Masja de Haas; Conny Brouwer; Anton Hagenbeek; Marinus H J van Oers; Sacha Zeerleder
Journal:  Blood       Date:  2013-02-14       Impact factor: 22.113

4.  Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.

Authors:  Anita Hill; Russell P Rother; Louise Arnold; Richard Kelly; Matthew J Cullen; Stephen J Richards; Peter Hillmen
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

5.  Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.

Authors:  Wilma Barcellini; Bruno Fattizzo; Anna Zaninoni; Tommaso Radice; Ilaria Nichele; Eros Di Bona; Monia Lunghi; Cristina Tassinari; Fiorella Alfinito; Antonella Ferrari; Anna Paola Leporace; Pasquale Niscola; Monica Carpenedo; Carla Boschetti; Nicoletta Revelli; Maria Antonietta Villa; Dario Consonni; Laura Scaramucci; Paolo De Fabritiis; Giuseppe Tagariello; Gianluca Gaidano; Francesco Rodeghiero; Agostino Cortelezzi; Alberto Zanella
Journal:  Blood       Date:  2014-09-16       Impact factor: 22.113

6.  Complement deposition in autoimmune hemolytic anemia is a footprint for difficult-to-detect IgM autoantibodies.

Authors:  Elisabeth M Meulenbroek; Masja de Haas; Conny Brouwer; Claudia Folman; Sacha S Zeerleder; Diana Wouters
Journal:  Haematologica       Date:  2015-09-09       Impact factor: 9.941

7.  Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia.

Authors:  Margaret A Lindorfer; Erika M Cook; Edimara S Reis; Daniel Ricklin; Antonio M Risitano; John D Lambris; Ronald P Taylor
Journal:  Clin Immunol       Date:  2016-08-18       Impact factor: 3.969

8.  Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.

Authors:  Antonio M Risitano; Daniel Ricklin; Yijun Huang; Edimara S Reis; Hui Chen; Patrizia Ricci; Zhuoer Lin; Caterina Pascariello; Maddalena Raia; Michela Sica; Luigi Del Vecchio; Fabrizio Pane; Florea Lupu; Rosario Notaro; Ranillo R G Resuello; Robert A DeAngelis; John D Lambris
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

9.  TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins.

Authors:  Ju Shi; Eileen L Rose; Andrew Singh; Sami Hussain; Nancy E Stagliano; Graham C Parry; Sandip Panicker
Journal:  Blood       Date:  2014-04-02       Impact factor: 22.113

10.  Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience.

Authors:  Maura Faraci; Marco Zecca; Marta Pillon; Attilio Rovelli; Maria Cristina Menconi; Mimmo Ripaldi; Franca Fagioli; Marco Rabusin; Ottavio Ziino; Edoardo Lanino; Franco Locatelli; Thomas Daikeler; Arcangelo Prete
Journal:  Biol Blood Marrow Transplant       Date:  2013-11-23       Impact factor: 5.742
View more
  2 in total

Review 1.  Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease.

Authors:  Esther C W de Boer; Anouk G van Mourik; Ilse Jongerius
Journal:  Front Immunol       Date:  2020-12-10       Impact factor: 7.561

2.  Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors.

Authors:  Christina Lamers; Xiaoguang Xue; Martin Smieško; Henri van Son; Bea Wagner; Nadja Berger; Georgia Sfyroera; Piet Gros; John D Lambris; Daniel Ricklin
Journal:  Nat Commun       Date:  2022-09-20       Impact factor: 17.694
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.